Pretomanid

Pretomanid
Clinical data
Trade names	Dovprela
Other names	PA-824
AHFS/Drugs.com	Monograph
MedlinePlus	a619056
License data	US DailyMed: Pretomanid;
Routes of; administration	By mouth
ATC code	J04AK08 (WHO) ;
Legal status
Legal status	US: ℞-only; EU: Rx-only;
Identifiers
	IUPAC name (6S)-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b] [1,3]oxazine;
CAS Number	187235-37-6;
PubChem CID	456199;
DrugBank	DB05154;
ChemSpider	401693 ;
UNII	2XOI31YC4N;
KEGG	D10722 ;
ChEMBL	ChEMBL227875 ;
CompTox Dashboard (EPA)	DTXSID8041163 ;
Chemical and physical data
Formula	C14H12F3N3O5
Molar mass	359.261 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1[C@@H](COC2=NC(=CN21)[N+](=O)[O-])OCC3=CC=C(C=C3)OC(F)(F)F;
	InChI InChI=1S/C14H12F3N3O5/c15-14(16,17)25-10-3-1-9(2-4-10)7-23-11-5-19-6-12(20(21)22)18-13(19)24-8-11/h1-4,6,11H,5,7-8H2/t11-/m0/s1 ; Key:ZLHZLMOSPGACSZ-NSHDSACASA-N ;

Pretomanid is an antibiotic medication used for the treatment of multi-drug-resistant tuberculosis affecting the lungs. It is generally used together with bedaquiline and linezolid. It is taken by mouth.

The most common side effects include nerve damage, acne, vomiting, headache, low blood sugar, diarrhea, and liver inflammation. It is in the nitroimidazole class of medications.

Pretomanid was approved for medical use in the United States in August 2019, and in the European Union in July 2020. Pretomanid was developed by TB Alliance. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication. It is on the World Health Organization's List of Essential Medicines.